Cat. No.: HY-109099

Pemigatinib

(Synonyms: INCB054828)

22 Cited Publications

Customer Review

Based on 22 publication(s) in Google Scholar

Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.

For research use only. We do not sell to patients.

Purity: 99.84%
CAS No.: 1513857-77-6
Formula: C₂₄H₂₇F₂N₅O₄
Molecular Weight:487.50

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Pemigatinib Chemical Structure

CAS No.: 1513857-77-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (22)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[2]

FGFR1

0.4 nM (IC₅₀)

FGFR2

0.5 nM (IC₅₀)

FGFR3

1.2 nM (IC₅₀)

FGFR4

30 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A204	IC₅₀	18.4 nM Compound: 1	Antiproliferation activity against human A204 cells harboring FGFR2 amplification incubated for 72 hrs by CCK8 assay Antiproliferation activity against human A204 cells harboring FGFR2 amplification incubated for 72 hrs by CCK8 assay	[PMID: 38718625]
AN3-CA	GI₅₀	0.132 μM Compound: 3	Antiproliferative activity against human AN3-CA cells harboring FGFR2 K310R/N549K mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against human AN3-CA cells harboring FGFR2 K310R/N549K mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	GI₅₀	>5 μM Compound: 3	Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	GI₅₀	>5 μM Compound: 3	Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR4 V550E mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR4 V550E mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	GI₅₀	0.005 μM Compound: 3	Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR3 assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR3 assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	GI₅₀	2.073 μM Compound: 3	Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR3-V555M mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR3-V555M mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
BaF3	GI₅₀	4.495 μM Compound: 3	Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR4 N535K mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring TEL-FGFR4 N535K mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
J82	GI₅₀	4.286 μM Compound: 3	Antiproliferative activity against human J82 cells harboring FGFR3 K652E mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against human J82 cells harboring FGFR3 K652E mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
KMS-11	GI₅₀	0.232 μM Compound: 3	Antiproliferative activity against human KMS-11 cells harboring FGFR3 Y373C mutant assessed as cell growth inhibition by CellTiter-Glo assay Antiproliferative activity against human KMS-11 cells harboring FGFR3 Y373C mutant assessed as cell growth inhibition by CellTiter-Glo assay	[PMID: 35436119]
MDA-MB-453	IC₅₀	73.7 nM Compound: 1	Antiproliferation activity against human MDA-MB-453 cells harboring FGFR4 Y367C mutant incubated for 72 hrs by CCK8 assay Antiproliferation activity against human MDA-MB-453 cells harboring FGFR4 Y367C mutant incubated for 72 hrs by CCK8 assay	[PMID: 38718625]
RT-112	IC₅₀	>1150 nM Compound: Pemigatinib	Antiproliferative activity against human RT-112 cells expressing FGFR3 V555M mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human RT-112 cells expressing FGFR3 V555M mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
RT-112	IC₅₀	174 nM Compound: Pemigatinib	Antiproliferative activity against human RT-112 cells expressing FGFR3 K650M mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human RT-112 cells expressing FGFR3 K650M mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
RT-112	IC₅₀	1880 nM Compound: Pemigatinib	Antiproliferative activity against human RT-112 cells expressing FGFR3 N540K mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human RT-112 cells expressing FGFR3 N540K mutant assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
RT-112	IC₅₀	23.7 nM Compound: 1	Antiproliferation activity against human RT-112 cells harboring FGFR3-TACC3 incubated for 72 hrs by CCK8 assay Antiproliferation activity against human RT-112 cells harboring FGFR3-TACC3 incubated for 72 hrs by CCK8 assay	[PMID: 38718625]
RT-112	IC₅₀	3.3 nM Compound: Pemigatinib	Antiproliferative activity against human RT-112 cells assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human RT-112 cells assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
RT-112	IC₅₀	6 nM Compound: Pemigatinib	Antiproliferative activity against human RT-112 cells expressing FGFR3 assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human RT-112 cells expressing FGFR3 assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
Sf9	IC₅₀	0.4 nM Compound: 2	Inhibition of N-terminal GST tagged recombinant human FGFR2 (400 to 821 residues) expressed in an Sf9 infected baculovirus expression system using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition and m Inhibition of N-terminal GST tagged recombinant human FGFR2 (400 to 821 residues) expressed in an Sf9 infected baculovirus expression system using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition and m	[PMID: 36356320]
Sf9	IC₅₀	1.7 nM Compound: 2	Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition a Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition a	[PMID: 36356320]
SNU-16	IC₅₀	3.9 nM Compound: Pemigatinib	Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay Antiproliferative activity against human SNU-16 cells assessed as inhibition of cell growth incubated for 5 days by Cell-titer glo assay	[PMID: 38267212]
SNU-16	IC₅₀	5.9 nM Compound: 1	Antiproliferation activity against human SNU-16 cells harboring FGFR2 amplification incubated for 72 hrs by CCK8 assay Antiproliferation activity against human SNU-16 cells harboring FGFR2 amplification incubated for 72 hrs by CCK8 assay	[PMID: 38718625]

In Vitro

Cells expressing the FGFR2-CLIP1 fusion is sensitive to Pemigatinib (INCB054828; IC₅₀ value 10.16 nM), while cells with added N549H mutation is resistant to Pemigatinib (IC₅₀ value of 1527.57 nM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1513857-77-6
Appearance Solid
Molecular Weight 487.50
Formula C₂₄H₂₇F₂N₅O₄
Color White to light yellow
SMILES

CCN(C(N(C(C(F)=C(OC)C=C1OC)=C1F)C2)=O)C(C2=CN3)=C4C3=NC(CN5CCOCC5)=C4
Synonyms

INCB054828
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (22)

All Cell Proliferation/Viability AssayIn Vivo ImagingWBRT-PCR2D/3D Cell Culture and Differentiation

Sort by:

Journal Impact Factor

Nature

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. [Abstract]

2022 Aug;608(7923):609-617. PMID: 35948633

Pemigatinib purchased from MedChemExpress. Usage Cited in: Nature. 2022 Aug;608(7923):609-617. [Abstract]

Half-maximum inhibitory concentration (IC₅₀) value quantifications of 2D-grown NMuMG cells expressing GFP or the indicated Fgfr2 variants and treated with AZD4547 or Pemigatinib for 4 days. Data are the mean of 5 independent experiments (GFP, Fgfr2FL, Fgfr2ΔE18) or 1 experiment (other Fgfr2 variants).

Pemigatinib purchased from MedChemExpress. Usage Cited in: Nature. 2022 Aug;608(7923):609-617. [Abstract]

Dose-response curves of indicated human cancer cell lines treated with Pemigatinib (0.01-10⁵ nM) for 4 days.
Cancer Res

The C-terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2. [Abstract]

2025 Jun 24. PMID: 40554806

Pemigatinib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Jun 24. [Abstract]

Growth rate (GR)-corrected dose–response curves of NMuMG cells expressing indicated Fgfr2 variants and treated for 4 days with Pemigatinib (10^-4-100 μM). Data are represented as mean ± SEM of n = 5 replicas per group.
Adv Sci (Weinh)

Synthetic Retinoid Sulfarotene Selectively Inhibits Tumor-Repopulating Cells of Intrahepatic Cholangiocarcinoma via Disrupting Cytoskeleton by P-Selectin/PSGL1 N-Glycosylation Blockage. [Abstract]

2024 Nov 28:e2407519. PMID: 39605300
Cell Death Dis

Growth factor receptor plasticity drives therapeutic persistence of metastatic breast cancer. [Abstract]

2025 Apr 4;16(1):251. PMID: 40185706

Pemigatinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 4;16(1):251. [Abstract]

T07 cells (5 × 10⁵) were injected into the tail vein of approximately 6-week-old female BALB/c mice, and after 3 days mice were randomized prior to dosing of Pemigatinib at (25 mg/kg; oral gavage). BLI of vehicle vs pemigatinib-treated mice on days 10 and 14. The results showed that Pemigatinib significantly reduced pulmonary tumor burden in these mice.

Pemigatinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 4;16(1):251. [Abstract]

4T07 cells were treated with Pemigatinib (Pemi, 10 nM) for the indicated amounts of time. Cells were lysed and analyzed by immunoblot for expression of PDGFR (α and β), ERK1/2 (phospho and total), and tubulin.

Pemigatinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 4;16(1):251. [Abstract]

4T07 cells were treated with Pemigatinib (10 nM) for 24 h and cells were analyzed by RT-PCR for expression of PDGFRa and PDGFRb.

Pemigatinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 4;16(1):251. [Abstract]

4T07 cells (2000 cells) were seeded under 3D culture conditions for 3 days at which point the cultures were left untreated (top row) or treated with Pemigatinib (50 nM; bottom row) for 96 h. Following drug treatment, cultures were allowed to recover in the absence or presence of PDGF-bb (100 ng/µL). Representative brightfield images are shown at the indicated days and treatment conditions.
Proc Natl Acad Sci U S A

The conserved fibroblast growth factor receptor-based signaling is required for dendrite regeneration. [Abstract]

2026 Mar 24;123(12):e2506886123. PMID: 41849383
Proc Natl Acad Sci U S A

Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. [Abstract]

2024 Feb 6;121(6):e2317756121. PMID: 38300868
NPJ Precis Oncol

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. [Abstract]

2021 Jul 16;5(1):66. PMID: 34272467
Mol Syst Biol

Illuminating phenotypic drug responses of sarcoma cells to kinase inhibitors by phosphoproteomics. [Abstract]

2024 Jan;20(1):28-55. PMID: 38177929
J Chem Inf Model

Probe Substrate Dependencies in CYP3A4 Allosteric Inhibition: A Novel Molecular Mechanism Involving F-F' Loop Perturbations. [Abstract]

2024 Mar 25;64(6):2058-2067. PMID: 38457234
Commun Biol

Exploiting collateral sensitivity in the evolution of resistance to tyrosine kinase inhibitors in soft tissue sarcomas. [Abstract]

2025 Aug 8;8(1):1185. PMID: 40781553
Int J Mol Sci

Inhibition of Fibroblast Growth Factor Receptor 3 Signaling by Ponatinib Reduces Growth and Cytokine Production of Multiple Myeloma Cells. [Abstract]

2026 Jun 9;27(12):5217. PMID: 42352940
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Luminescence

A green and highly sensitive microwell spectrofluorimetric method with high throughput for the determination of pemigatinib based on dual fluorescence enhancement by photoinduced electron transfer blocking and micellization: Application to the analysis of tablets, content uniformity testing, and human plasma. [Abstract]

2024 Jun;39(6):e4813. PMID: 38922756
Separations

2023 Apr 10, 10(4), 247.
BMJ Open Ophthalmol

Impact of anticancer drugs on human Tenon's fibroblast proliferation: implications for glaucoma surgery. [Abstract]

2026 Jan 12;11(1):e002307. PMID: 41526033
Biochem Biophys Res Commun

Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells. [Abstract]

2024 Jan 8:691:149314. PMID: 38039831
Anticancer Drugs

Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models. [Abstract]

2023 Oct 1;34(9):1035-1045. PMID: 36729099
Technical University of Dresden

2025.
University of Auckland

2025.
SSRN

2025 Jul 4.
Preprints

2024 Mar 20.
Research Square Preprint

2024 Jan 31.

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (51.28 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0513 mL

10.2564 mL

20.5128 mL

5 mM

0.4103 mL

2.0513 mL

4.1026 mL

10 mM

0.2051 mL

1.0256 mL

2.0513 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.75 mg/mL (5.64 mM); Clear solution

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (4.27 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790. [Content Brief]

[2]. Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567. [Content Brief]

[3]. Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4). [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0513 mL	10.2564 mL	20.5128 mL	51.2821 mL
	5 mM	0.4103 mL	2.0513 mL	4.1026 mL	10.2564 mL
	10 mM	0.2051 mL	1.0256 mL	2.0513 mL	5.1282 mL
	15 mM	0.1368 mL	0.6838 mL	1.3675 mL	3.4188 mL
	20 mM	0.1026 mL	0.5128 mL	1.0256 mL	2.5641 mL
	25 mM	0.0821 mL	0.4103 mL	0.8205 mL	2.0513 mL
	30 mM	0.0684 mL	0.3419 mL	0.6838 mL	1.7094 mL
	40 mM	0.0513 mL	0.2564 mL	0.5128 mL	1.2821 mL
	50 mM	0.0410 mL	0.2051 mL	0.4103 mL	1.0256 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Pemigatinib

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Therapy Drug Library

Angiogenesis-Related Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

FDA Kinase Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) Pemigatinib

Biological Activity

Chemical Information

Publications (22)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Pemigatinib Related Classifications

HY-109099 Related Classifications